Inferior outcome of bone metastasis in non-small-cell-lung-cancer patients treated with epidermal growth factor receptor inhibitors

BACKGROUND: Targeted therapy has been established as the standard-of-care for patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. Among patients with advanced lung cancer, 30–40% have bone metastases (BoM) at first diagnosis. However, lit...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yue-Yun, Wang, Pei-Pei, Fu, Yang-, Li, Qing-, Tian, Jiang-Fang, Liu, Ting-, Lin, Zhen, Ding, Zhen-Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8138759/
https://www.ncbi.nlm.nih.gov/pubmed/34036039
http://dx.doi.org/10.1016/j.jbo.2021.100369

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8138759/
https://www.ncbi.nlm.nih.gov/pubmed/34036039
http://dx.doi.org/10.1016/j.jbo.2021.100369

Ejemplares similares